Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
464 stopped studies mapped to Malignant Central Nervous System Neoplasm and descendants · 90% state a reason
Over the 464 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05324501 | A Study of Intra-tumoral Administered MTX110 in Patients With Recurrent Glioblastoma(MAGIC-G1) | Phase 1 | terminated | Apr 12, 2022 | Biodexa Pharmaceuticals | Strategic decision | Sponsor / business decision |
| NCT01814813 | Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With… | Phase 2 | terminated | Mar 20, 2013 | Alliance for Clinical Trials in Oncology | DSMB futility analysis | Efficacy / futility |
| NCT03717142 | Feasibility of the LUM Imaging System for Detection of Cancer to the Brain | N/A | terminated | Oct 24, 2018 | Lumicell, Inc. | Initial data indicated a change in study design required prior to collecting additional data. | Other (stated, no rule matched) |
| NCT04397679 | Partial Brain RT, Temozolomide, Chloroquine, and TTF Therapy for the Treatment of Newly… | Phase 1 | terminated | May 21, 2020 | Barbara Ann Karmanos Cancer Institute | slow accrual | Enrollment / accrual |
| NCT06328036 | Testing the Combination of Anti-cancer Drugs Tiragolumab and Atezolizumab to Improve… | Phase 2 | withdrawn | Mar 25, 2024 | National Cancer Institute (NCI) | Other - Protocol moved to Disapproved | Other (stated, no rule matched) |
| NCT02525692 | Oral ONC201 in Adult Recurrent Glioblastoma | Phase 2 | terminated | Aug 17, 2015 | Jazz Pharmaceuticals | The Sponsor terminated the study to prioritize enrollment in a randomized Phase 3 trial of ONC201… | Safety / toxicity |
| NCT05500508 | Oral AMXT 1501 Dicaprate in Combination With IV DFMO | Phase 1 / Phase 2 | terminated | Aug 15, 2022 | Aminex Therapeutics, Inc. | Required re-formulation of DFMO from IV to capsule to maintain safety | Safety / toxicity |
| NCT04771897 | A Study of BXQ-350 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma…(KONQUER) | Phase 1 | terminated | Feb 25, 2021 | Bexion Pharmaceuticals, Inc. | Bexion Pharmaceuticals has decided to close the BXQ-350.AD study to enrollment prior to the… | Enrollment / accrual |
| NCT04421378 | A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or… | Phase 1 / Phase 2 | terminated | Jun 9, 2020 | Karyopharm Therapeutics Inc | Upon further consideration of the existing data and the competitive landscape, Karyopharm… | Other (stated, no rule matched) |
| NCT05973903 | Lenvatinib, Pembrolizumab, and Tumor Treating Fields (TTFields) for Second-line Treatment… | Phase 1 / Phase 2 | withdrawn | Aug 3, 2023 | Tel Aviv Medical Center | It was decided by the researcher not to open the study due to administrative issues. | Other (stated, no rule matched) |
| NCT04128774 | Function and Composition of Regulatory B Cells in Participants With Glioblastoma(GBMdexaB) | — | terminated | Oct 16, 2019 | Amsterdam UMC, location VUmc | To few participants | Other (stated, no rule matched) |
| NCT05879120 | Randomized Study of Neo-adjuvant and Adjuvant Pembrolizumab With and Without Targeted… | Phase 2 | withdrawn | May 30, 2023 | M.D. Anderson Cancer Center | PI Request | Other (stated, no rule matched) |
| NCT02372409 | Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain… | Phase 2 | terminated | Feb 26, 2015 | Washington University School of Medicine | Low accruals and competing clinical trials | Enrollment / accrual |
| NCT03973918 | Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG(BRAF) | Phase 2 | terminated | Jun 4, 2019 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | NCI decided to terminate ABTC Consortium due to NCI moving in different direction for Brain Cancer | Other (stated, no rule matched) |
| NCT04521946 | Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade… | Phase 1 | withdrawn | Aug 21, 2020 | M.D. Anderson Cancer Center | No participants enrolled. | Enrollment / accrual |
| NCT04952571 | Combined Treatment of Camrelizumab and Bevacizumab for Adult Patients with Recurrent… | Phase 2 | terminated | Jul 7, 2021 | Beijing Sanbo Brain Hospital | Lack of funds | Funding |
| NCT03990597 | StrataXRT in Preventing Radiation Dermatitis in Pediatric Patients Undergoing Radiation… | Phase 1 | withdrawn | Jun 19, 2019 | M.D. Anderson Cancer Center | Per PI | Other (stated, no rule matched) |
| NCT03363659 | Disulfiram and Copper Gluconate With Temozolomide in Unmethylated Glioblastoma Multiforme | Phase 2 | terminated | Dec 6, 2017 | Wake Forest University Health Sciences | Investigator decision | Investigator |
| NCT06625359 | High-dose Chemotherapy with Thiotepa, Busulfan, and Cyclophosphamide Followed by… | Phase 2 | terminated | Oct 3, 2024 | Seoul National University Hospital | slow enrollment | Enrollment / accrual |
| NCT01246869 | Assessment of Primary and Metastatic Brain Tumor Hypoxia With Fluoromisonidazole, FDG and… | Phase 1 | terminated | Nov 23, 2010 | University of Utah | PI retired, study closed | Other (stated, no rule matched) |
| NCT05123534 | A Phase 2 Study of Sonodynamic Therapy Using SONALA-001 and Exablate 4000 Type 2.0 in… | Phase 2 | suspended | Nov 17, 2021 | SonALAsense, Inc. | The study is suspended due to lack of funding but not due to safety concerns. | Safety / toxicity |
| NCT05773664 | Dexamethasone and Azeliragon for Management of Post-Resection Cerebral Edema in Patients… | Phase 1 | withdrawn | Mar 17, 2023 | City of Hope Medical Center | Funding | Funding |
| NCT00555399 | Vorinostat, Isotretinoin and Temozolomide in Adults With Recurrent Glioblastoma… | Phase 1 / Phase 2 | terminated | Nov 8, 2007 | M.D. Anderson Cancer Center | No Sponsor funding for continuation of trial | Funding |
| NCT03539731 | [18F]DASA-23 and PET Scan in Evaluating Pyruvate Kinase M2 Expression in Patients With… | Phase 1 | terminated | May 29, 2018 | Guido A. Davidzon, MD, SM | study did not meet its objectives due to difficulties in enrollment | Enrollment / accrual |
| NCT01483820 | Safety and Efficacy Study of TPI-287 in Neuroblastoma and Medulloblastoma | Phase 1 / Phase 2 | terminated | Dec 1, 2011 | Giselle Sholler | Lack of enrollment | Enrollment / accrual |
| NCT04324840 | A Study of CC-90010 in Combination With Temozolomide With or Without Radiation Therapy in… | Phase 1 | terminated | Mar 27, 2020 | Celgene | Business objectives have changed | Sponsor / business decision |
| NCT05370508 | A Study of Sonodynamic Therapy Using SONALA-001 and Exablate 4000 Type 2.0 in Subjects… | Phase 1 / Phase 2 | terminated | May 11, 2022 | SonALAsense, Inc. | Study is terminated due to funding challenges and not due to safety concerns. | Safety / toxicity |
| NCT04047303 | CNS Penetration, PK and PD of Preoperative CC-90010 in Progressive/Recurrent Diffuse… | Phase 1 | terminated | Aug 6, 2019 | Celgene | Business objectives have changed. | Sponsor / business decision |
| NCT03250299 | Microtubule-Targeted Agent BAL101553 and Radiation Therapy in Treating Patients With… | Phase 1 | terminated | Aug 15, 2017 | Basilea Pharmaceutica | Due to the National Cancer Institute's (NCI)-mandated termination of the Adult Brain Tumor… | Other (stated, no rule matched) |
| NCT04221061 | 18F-FluorThanatrace (PET/CT) in Glioblastoma | Early Phase 1 | terminated | Jan 9, 2020 | University of Pennsylvania | Companion treatment trial closed early with negative results. No imaging study participants… | Other (stated, no rule matched) |
| NCT02924038 | A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II… | Phase 1 | terminated | Oct 5, 2016 | Nicholas Butowski | Industry sponsor decision | Sponsor / business decision |
| NCT04915404 | Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme (WHO Grade IV) | Phase 1 / Phase 2 | terminated | Jun 7, 2021 | WPD Pharmaceuticals Sp. z o.o. | Business decision | Sponsor / business decision |
| NCT01622764 | 89Zr-RO5323441 PET Imaging in Glioblastoma | Phase 2 | withdrawn | Jun 19, 2012 | University Medical Center Groningen | No funding from the sponsor | Funding |
| NCT02624388 | Study of Genistein in Pediatric Oncology Patients (UVA-Gen001)(UVA-Gen001) | Phase 2 | terminated | Dec 8, 2015 | University of Virginia | Poor enrollment | Enrollment / accrual |
| NCT05074992 | A Trial of Neoadjuvant Therapy in Patients With Newly Diagnosed Glioblastoma(NeAT Glio) | Phase 2 | terminated | Oct 12, 2021 | University College, London | Support withdrawn from drug company supplying IMP | Sponsor / business decision |
| NCT04681677 | Recurrent GBM Treated With Neurosurgical Resection and IORT Using the Xoft Axxent eBx…(IORT) | Phase 2 | terminated | Dec 23, 2020 | Xoft, Inc. | unspecified business decision | Sponsor / business decision |
| NCT02085304 | Tumor Resection and Gliadel® Wafers, Followed by Temodar® With Standard Radiation or… | Phase 1 / Phase 2 | terminated | Mar 12, 2014 | St. Joseph's Hospital and Medical Center, Phoenix | met stopping rules for futility | Efficacy / futility |
| NCT02880410 | Feasibility Study on LITT for Newly Diagnosed Glioblastoma(FLAG) | Phase 1 | terminated | Aug 26, 2016 | Monteris Medical | Terminated (failure to enroll) | Enrollment / accrual |
| NCT03927222 | Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed WHO Grade…(I-ATTAC) | Phase 2 | terminated | Apr 25, 2019 | Mustafa Khasraw, MBChB, MD, FRCP, FRACP | Resource shortage | Other (stated, no rule matched) |
| NCT05304663 | Safety and Efficacy of Different Administration Sequences of L19TNF With Lomustine in…(GLIOASTRA) | Phase 1 | withdrawn | Mar 31, 2022 | Philogen S.p.A. | The Sponsor had no further plan for the study in object | Other (stated, no rule matched) |
| NCT02133183 | Sapanisertib Before and After Surgery in Treating Patients With Recurrent Glioblastoma | Phase 1 | terminated | May 7, 2014 | National Cancer Institute (NCI) | Other - Lapse in funding | Funding |
| NCT02546102 | Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma | Phase 3 | suspended | Sep 10, 2015 | Precision Life Sciences Group | Company is discussing with FDA to reinitiate the trial now. | Sponsor / business decision |
| NCT05952687 | Trial of Idasanutlin and Selinexor Therapy for Children With Progressive/Relapsed AT/RT… | Phase 1 | withdrawn | Jul 19, 2023 | St. Jude Children's Research Hospital | Drug withdrawn by company. | Sponsor / business decision |
| NCT05666349 | Reirradiation and Niraparib in Patients With Recurrent Glioblastoma(RiNG) | Phase 1 | withdrawn | Dec 27, 2022 | University College, London | Funder support withdrawn 13-Oct-2023. Study did not open to recruitment. | Enrollment / accrual |
| NCT03705351 | Tumor Treating Fields With Chemoradiation in Newly Diagnosed GBM | Phase 1 | terminated | Oct 15, 2018 | Providence Health & Services | Prinicipal Investigator departure from institution | Investigator |
| NCT03403361 | Dual-Energy CT on Plan Quality, Dose-delivery Accuracy, and Simulated Outcomes of… | N/A | terminated | Jan 18, 2018 | Washington University School of Medicine | Low accrual | Enrollment / accrual |
| NCT02905643 | Discerning Pseudoprogression vs True Tumor Growth in GBMs | — | terminated | Sep 19, 2016 | Ascension Health | Investigator left institution | Investigator |
| NCT04341311 | Phase I Study of Marizomib + Panobinostat for Children With DIPG(DIPG) | Phase 1 | terminated | Apr 10, 2020 | Dana-Farber Cancer Institute | Withdrawal of support from BMS | Other (stated, no rule matched) |
| NCT02768337 | Cambridge Brain Mets Trial 1(CamBMT1) | Phase 1 / Phase 2 | terminated | May 11, 2016 | Cambridge University Hospitals NHS Foundation Trust | Slow recruitment | Enrollment / accrual |
| NCT02168270 | Temozolomide and Ascorbic Acid in Treating Patients With Recurrent High-Grade Glioma | Phase 1 | terminated | Jun 20, 2014 | University of Nebraska | not stated | Not stated |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Feb 10, 2025source: clinicaltrials